Cargando…

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Trastuzumab is a standard treatment for HER2-positive (HER2(+)) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2(+) metastatic breast cancer (MBC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Huiping, Liu, Jiang, Chen, Jianing, Wang, Huiyun, Yang, Linbin, Chen, Fei, Fan, Siting, Wang, Jing, Shao, Bin, Yin, Dong, Zeng, Musheng, Li, Mengfeng, Li, Jun, Su, Fengxi, Liu, Qiang, Yao, Herui, Su, Shicheng, Song, Erwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915573/ https://www.ncbi.nlm.nih.gov/pubmed/29691399 http://dx.doi.org/10.1038/s41467-018-03537-w

Ejemplares similares

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Gong, Chang, et al.
Publicado: (2016)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program
por: Su, Shicheng, et al.
Publicado: (2015)

Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer
por: Gong, Chang, et al.
Publicado: (2010)

Long Noncoding RNA Expression Signatures of Metastatic Nasopharyngeal Carcinoma and Their Prognostic Value
por: Zhang, Wei, et al.
Publicado: (2015)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer
por: Su, Shicheng, et al.
Publicado: (2017)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Nerve Fibers in Breast Cancer Tissues Indicate Aggressive Tumor Progression
por: Huang, Di, et al.
Publicado: (2014)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
por: Li, Huiping, et al.
Publicado: (2016)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2021)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time
por: da Luz, Felipe Andrés Cordero, et al.
Publicado: (2022)

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
por: Ling, Yun, et al.
Publicado: (2022)

Breast-conserving Surgery Rates in Breast Cancer Patients With Different Molecular Subtypes: An Observational Study Based on Surveillance, Epidemiology, and End Results (SEER) Database
por: Chen, Kai, et al.
Publicado: (2016)

A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer
por: Ma, Tingting, et al.
Publicado: (2022)

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
por: Yang, Hai-Yuan, et al.
Publicado: (2017)

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer
por: Hu, Xingbin, et al.
Publicado: (2023)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
por: He, Lin, et al.
Publicado: (2019)

MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC
por: Fang, Lishan, et al.
Publicado: (2018)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
por: Liu, Xiaoyun, et al.
Publicado: (2022)

Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis
por: Tan, Weige, et al.
Publicado: (2016)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/β-catenin signaling
por: Guan, Hongyu, et al.
Publicado: (2019)

EGF-induced nuclear localization of SHCBP1 activates β-catenin signaling and promotes cancer progression
por: Liu, Lei, et al.
Publicado: (2018)

HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy
por: Jia, Haixia, et al.
Publicado: (2014)

Author Correction: Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
por: Yang, Hai-Yuan, et al.
Publicado: (2018)

Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type
por: Xu, Chen, et al.
Publicado: (2017)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC
por: Chung, Wei-Pang, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2uk1dv3cs4r0s6lce5f7hn0eeu